Tumour-positive sentinel node findings in patients with ductal carcinoma in situ

Journal of Surgical Oncology

Volumn 94, Issue 5, 2006, Pages 380-384

  Leidenius, M ^a   Salmenkivi, K ^a   Von Smitten, K ^a   Heikkila, P ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Axillary clearance; Isolated tumour cells; Micrometastases; Sentinel node biopsy

Indexed keywords

ARTICLE; BREAST CANCER; BREAST CONSERVATION SURGERY; BREAST SURGERY; CANCER INVASION; CARCINOMA IN SITU; DUCTAL CARCINOMA IN SITU; FEMALE; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOLATED TUMOR CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MICROMETASTASIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; TUMOR CELL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; PALPATION; PROSPECTIVE STUDIES; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY;

EID: 33749064721     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20581     Document Type: Article

References (21)

1. Silverstein MJ: Ductal carcinoma in situ of the breast. Annu Rev Med 2000;51:17-32.
2. Cody HS III, Klauber-Demore N, Borgen PI, et al.: Is it really duct carcinoma in situ? Ann Surg Oncol 2001;8:617-619.
3. Cox CE, Nguyen K, Gray RJ, et al.: Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): Why map DCIS? Am Surg 2001;67:513-519 (discussion 519-521).
4. Intra M, Veronesi P, Mazzarol G, et al.: Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg 2003;138:309-313.
5. Klauber-DeMore N, Tan LK, Liberman L, et al.: Sentinel lymph node biopsy: Is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000;7:636-642.
6. Mittendorf ME, Arciero CA, Gutchell V, et al.: Core biopsy diagnosis of ductal carcinoma in situ: An indication for sentinel lymph node biopsy. Curr Surg 2005;62:253-257.
7. Pendas S, Dauway E, Giuliano R, et al.: Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol 2000;7:15-20.
8. Veronesi P, Intra M, Vento AR, et al.: Sentinel lymph node biopsy for localised ductal carcinoma in situ? Breast 2005;14:520-522.
9. Yen TW, Hunt KK, Ross MI, et al.: Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: A guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 2005; 200:516-526.
10. Zavagno G, Carcoforo P, Marconato R, et al.: Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. BMC Cancer 2005;5:28.
11. Hansen NM, Ye X, Grube BJ, et al.: Manipulation of the primary breast tumor and the incidence of sentinel node metastases from invasive breast cancer. Arch Surg 2004;139:634-639 (discussion 639-640).
12. Diaz NM, Cox CE, Ebert M, et al.: Benign mechanical transport of breast epithelial cells to sentinel lymph nodes. Am J Surg Pathol 2004;28:1641-1645.
13. Leidenius MH, Krogerus LA, Toivonen TS, et al.: Sentinel node biopsy is not sensible in breast cancer patients with large primary tumours. Eur J Surg Oncol 2005;31:364-368.
14. Silverstein MJ, Poller DN, Waisman JR, et al.: Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345:1154-1157.
15. Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer 1997;80: 1798-1802.
16. American Joint Committee on Cancer: Cancer staging manual. New York: Springer-Verlag; 2002.
17. UICC: TNM classification of malignant tumours. New York: John Wiley and Sons; 2002.
18. Intra M, Zurrida S, Maffini F, et al.: Sentinel lymph node metastasis in microinvasive breast cancer. Ann Surg Oncol 2003; 10:1160-1165.
19. Tamhane R, Dahlstrom JE, Mccallum DD, et al.: The clinical significance of cytokeratin-positive cells in lymphnodes at the time of mastectomy from patient with ductal carcinoma-in situ. Ann Surg Oncol 2002;9:999-1003.
20. Lara JF, Young SM, Velilla RE, et al.: The relevance of occult axillary micrometatases in ductal carcinoma in situ. Cancer 2003; 98:2104-2113.
21. El-Tamer M, Chun J, Gill M, et al.: Incidence and clinical significance of lymph node metastasis detected by cytokeratin immunohistochemical staining in ductal carcinoma in situ. Ann Surg Oncol 2005;12:254-259.